Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ASLN NASDAQ:GRTX NASDAQ:KRBP NASDAQ:SPRC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASLNASLAN Pharmaceuticals$0.60$0.60$0.48▼$25.44$1.23M1.4122,322 shsN/AGRTXGalera Therapeutics$0.02-18.6%$0.02$0.02▼$0.08$1.62M1.990,267 shs1,727 shsKRBPKiromic BioPharma$1.16$0.16▼$3.32$330K1.6611,347 shs107,749 shsSPRCSciSparc$1.80-0.6%$5.04$1.75▼$37.59$970K0.861.04 million shs117,195 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASLNASLAN Pharmaceuticals0.00%0.00%0.00%0.00%0.00%GRTXGalera Therapeutics-18.60%+7.36%-22.22%-37.50%-74.26%KRBPKiromic BioPharma0.00%0.00%0.00%0.00%-88.33%SPRCSciSparc-0.55%-19.28%-60.09%-72.17%-71.43%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASLNASLAN Pharmaceuticals$0.60$0.60$0.48▼$25.44$1.23M1.4122,322 shsN/AGRTXGalera Therapeutics$0.02-18.6%$0.02$0.02▼$0.08$1.62M1.990,267 shs1,727 shsKRBPKiromic BioPharma$1.16$0.16▼$3.32$330K1.6611,347 shs107,749 shsSPRCSciSparc$1.80-0.6%$5.04$1.75▼$37.59$970K0.861.04 million shs117,195 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASLNASLAN Pharmaceuticals0.00%0.00%0.00%0.00%0.00%GRTXGalera Therapeutics-18.60%+7.36%-22.22%-37.50%-74.26%KRBPKiromic BioPharma0.00%0.00%0.00%0.00%-88.33%SPRCSciSparc-0.55%-19.28%-60.09%-72.17%-71.43%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceASLNASLAN Pharmaceuticals 0.00N/AN/AN/AGRTXGalera Therapeutics 0.00N/AN/AN/AKRBPKiromic BioPharma 0.00N/AN/AN/ASPRCSciSparc 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookASLNASLAN Pharmaceuticals$12M0.10N/AN/A($6.50) per share-0.09GRTXGalera TherapeuticsN/AN/AN/AN/A($2.41) per shareN/AKRBPKiromic BioPharmaN/AN/AN/AN/A($8.29) per shareN/ASPRCSciSparc$1.31M0.73N/AN/A$18.13 per share0.10Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateASLNASLAN Pharmaceuticals-$44.22M-$21.92N/A∞N/AN/A-8,454.87%-121.60%N/AGRTXGalera Therapeutics-$59.08M-$0.19N/A∞N/AN/AN/A-99.34%N/AKRBPKiromic BioPharma-$26.90M-$3.50N/AN/AN/AN/AN/A-277.46%N/ASPRCSciSparc-$6.28MN/A0.00∞N/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthASLNASLAN PharmaceuticalsN/AN/AN/AN/AN/AGRTXGalera TherapeuticsN/AN/AN/AN/AN/AKRBPKiromic BioPharmaN/AN/AN/AN/AN/ASPRCSciSparcN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioASLNASLAN PharmaceuticalsN/A1.051.05GRTXGalera TherapeuticsN/A9.749.74KRBPKiromic BioPharmaN/A0.160.22SPRCSciSparcN/A5.365.28Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipASLNASLAN Pharmaceuticals58.82%GRTXGalera Therapeutics50.77%KRBPKiromic BioPharma10.91%SPRCSciSparc25.06%Insider OwnershipCompanyInsider OwnershipASLNASLAN Pharmaceuticals4.69%GRTXGalera Therapeutics12.90%KRBPKiromic BioPharma20.59%SPRCSciSparc1.52%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableASLNASLAN Pharmaceuticals302.04 million1.95 millionOptionableGRTXGalera Therapeutics3075.46 million47.38 millionOptionableKRBPKiromic BioPharma601.57 million1.22 millionNot OptionableSPRCSciSparc4530,000527,000Not OptionableKRBP, GRTX, ASLN, and SPRC HeadlinesRecent News About These CompaniesSciSparc (NASDAQ:SPRC) Upgraded to "Sell" at Wall Street ZenSeptember 14 at 3:55 AM | americanbankingnews.comSciSparc Ltd. (NASDAQ:SPRC) Short Interest UpdateSeptember 12, 2025 | americanbankingnews.comSciSparc Shareholders Approve Merger with AutoMaxAugust 28, 2025 | tipranks.comSciSparc: AutoMax's Shareholders Approve Merger with SciSparcAugust 28, 2025 | globenewswire.comSciSparc Ltd. Shareholders Approve Merger with AutoMax Motors Ltd. to Expand into Automotive SectorAugust 28, 2025 | quiverquant.comQSciSparc Shareholders Approve Merger with a Leading Parallel Vehicle Importer in IsraelAugust 28, 2025 | globenewswire.comSciSparc Shareholders Approve Key Proposals at August MeetingAugust 26, 2025 | msn.comSciSparc Ltd. Reschedules Special Shareholder Meeting Due to Lack of QuorumAugust 25, 2025 | tipranks.comSciSparc Announces Patent Filing and Merger UpdatesAugust 8, 2025 | theglobeandmail.comSciSparc and Clearmind Publish Patent for Novel Obesity TherapyAugust 8, 2025 | tipranks.comSciSparc Ltd. and Clearmind Medicine Inc. Collaborate to Launch International Patent Application for Innovative Therapy Targeting Metabolic Syndrome and ObesityAugust 7, 2025 | quiverquant.comQSciSparc-Clearmind Collaboration Leads to Publication of International Patent Application for Novel Combination Therapy Targeting Obesity and High Blood SugarAugust 7, 2025 | globenewswire.comSciSparc Ltd: SciSparc Announces Updates Regarding Proposed Merger; Form F-4 Registration Statement Has Been Declared Effective by SECJuly 31, 2025 | finanznachrichten.deSciSparc Announces Updates Regarding Proposed Merger; Form F-4 Registration Statement Has Been Declared Effective by SECJuly 30, 2025 | globenewswire.comClearmind Medicine files international patent application under PCTJuly 30, 2025 | msn.comSciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Combination Therapy Targeting Weight Loss and Fatty Liver DiseaseJuly 30, 2025 | globenewswire.comSciSparc Ltd. Regains Nasdaq ComplianceJuly 22, 2025 | tipranks.comSciSparc Ltd. Regains Compliance with Nasdaq Minimum Bid Price NotificationJuly 22, 2025 | globenewswire.comSciSparc Announces 1-for-21 Reverse Share Split - MorningstarJune 26, 2025 | morningstar.comMSciSparc Ltd. Adjourns Annual Meeting Due to Lack of QuorumJune 25, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeKRBP, GRTX, ASLN, and SPRC Company DescriptionsASLAN Pharmaceuticals NASDAQ:ASLN$0.60 0.00 (0.00%) As of 09/12/2025ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises eblasakimab (ASLAN004), a monoclonal antibody that targets the IL-13 receptor a1 subunit which is under Phase 2 developed for the treatment of atopic dermatitis and other immunology indications; and farudodstat (ASLAN003), an orally active, potent inhibitor of human dihydroorotate dehydrogenase currently under Phase 2 clinical trials for the treatment of autoimmune diseases. It has research collaboration agreement with Zenyaku Kogyo Co., Ltd. for the development and commercialization of eblasakimab in atopic dermatitis and all other indications in Japan. The company was founded in 2010 and is headquartered in Singapore.Galera Therapeutics NASDAQ:GRTX$0.02 0.00 (-18.60%) As of 09/15/2025 12:51 PM EasternGalera Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule dismutase mimetic for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and for patients with HNC undergoing standard-of-care radiotherapy. It also develops rucosopasem manganese (rucosopasem) to augment the anti-cancer efficacy of stereotactic body radiation therapy in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is based in Malvern, Pennsylvania.Kiromic BioPharma NASDAQ:KRBPKiromic BioPharma, Inc., a clinical stage biotherapeutics company, utilizes engineered and non-engineered Gamma Delta T cell (GDT) technologies to develop therapies for solid tumors. The company develops Deltacel-01, which is in Phase 1 clinical trial, for patients with non-small cell lung cancer; Isocel in combination with low-dose radiation to treat Mesothelin Isoform 2 positive solid malignancies; ALEXIS-ISO-1, an allogeneic GDT therapy product that targets an isoform of mesothelin; Procel in combination with low-dose radiation to treat PD-L1 positive solid malignancies; and ALEXIS-PRO-1, an allogeneic GDT therapy product that targets PD-L1. It has a license agreement with Longwood University; and a research and development collaboration agreement with Molipharma, S.R.L. The company was formerly known as Kiromic, Inc. and changed its name to Kiromic BioPharma, Inc. in December 2019. Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas.SciSparc NASDAQ:SPRC$1.80 -0.01 (-0.55%) Closing price 09/15/2025 04:00 PM EasternExtended Trading$1.77 -0.03 (-1.67%) As of 09/15/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution. The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and CannAmide, a palmitoylethanolamide oral tablet in softgel capsule form. It also has an agreement with The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation; and a collaboration with Clearmind Medicine Inc. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv-Yafo, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Commercial Growth Story Is Just Getting Started The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Reddit Hits Record Highs: Why Wall Street Is Taking Notice Royal Caribbean's 33% Dividend Hike Signals Deeper Growth FuelCell Energy's Stock: Is a Fundamental Breakout Underway? After a Strong Wall Street Debut, Klarna's Real Work Begins MarketBeat Week in Review – 09/08 - 09/12 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
